Popular antidepressants may reduce or cancel altogether the benefits of tamoxifen for women with breast cancer, according to new research.
The study, published in the British medical journal found that selective serotonin reuptake inhibitors (SSRIs) paroxetine was associated with an increased risk of breast cancer in combination with tamoxifen, whereas other antidepressants were.
“Up to 25 percent of patients with breast cancer experience a depressive disorder,” study authors wrote.
“Newer antidepressants are widely used in women with breast cancer for treatment of depression and prescribed tamoxifen for related tidal and various other signs.
Researchers argue that their findings confirmed the hypothesis that inhibitors of CYP2D6 such as paroxetine reduced the effectiveness of tamoxifen.
They said that would be required to suffer from breast cancer “drugs with low ability to inhibit CYP2D6, such as citalopram or venlafaxine.
Australian product information (PI) for paroxetine, there is mention of its role in reducing the efficacy of breast cancer, but tamoxifen AP mentions nothing about paroxetine.
“Currently, the information contained in the summary of product characteristics of various tamoxifen and paroxetine does not match,” the study’s authors wrote in an editorial accompanying.
“Promotion paroxetine drug tamoxifen interaction among physicians and pharmacists and the harmonization of the summary of product characteristics should be.
Buy xenical | Buy trazodone | Buy vicodin | Buy codeine


